Pomegranate (Punica granatum L.) peel extract ameliorates metabolic syndrome risk factors in patients with non-alcoholic fatty liver disease: a randomized double-blind clinical trial

Table 6 Liver elastography results of placebo and PP during the intervention

Variables	Study group	Before	P _value	After	P _value*	Changes	P _value**	P _value#
Liver stiffness (Kilo Pascal)	Placebo	5. 1 ± 0.56	0.07	5.24 ± 0.55	< 0.001	0.14 ± 0.02	< 0.001	< 0.001
Liver stiffness (Kilo Pascal)	PP	5.43 ± 0.39	0.07	4.71 ± 0.47	< 0.001	-0.72 ± 0.35	< 0.001	< 0.001
Hepatorenal ultrasound index	Placebo	1.82 ± 0.24	0.06	1.9 ± 0.27	0.03	0.07 ± 0.05	< 0.001	< 0.001
Hepatorenal ultrasound index	PP	1.98 ± 0.25	0.06	1.66 ± 0.19	< 0.001	− 0.30 ± 0.17	< 0.001	< 0.001

Data is presented as Mean ± SD.
P and P** are extracted from 2 independent sample t test. P* is extracted from paired t test for raw model. Also, P^# is presented adjusted model by baseline values, and potential confounders including weight, energy intake and physical activity, with ANCOVA.
“Changes” represent before and after changes in raw model; “PP” is for Pomegranate Peel group.

ISSN: 1475-2891